AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 830372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial endotoxin (5 ng/kg)
Number of subjects: 18
Study 830372 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiocholanolone (0.3 mg/kg)
Number of subjects: 18
Study 830372 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 18
Study 830372 — intervention group
Group type: COMPARATOR
Intervention: Control (propylene glycol)
Number of subjects: 18
Study 31965432 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikamana intervention (modified Next Step Counseling + peer support)
Number of subjects: 60
Study 31965432 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 30289355 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab 12 mg
Number of subjects: 0
Study 30289355 — intervention group
Group type: COMPARATOR
Intervention: SC IFNB-1a 44 μg
Number of subjects: 0
Study 29059133 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0657 (7 mg)
Number of subjects: 22
Study 25935606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Collagen Meniscus Implant (CMI)
Number of subjects: 43
Study 23730996 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 125
Study 23730996 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 125
Study 20177755 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily breastfeeding log for a minimum of 3 weeks
Number of subjects: 86
Study 20177755 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 19302077 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoanaesthesia (VisThesia)
Number of subjects: 98
Study 19302077 — intervention group
Group type: COMPARATOR
Intervention: Intracameral lidocaine (0.5 cc of 1% unpreserved lidocaine)
Number of subjects: 98
Study 17034604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical therapy based on in vitro cytotoxicity assay
Number of subjects: 47
Study 17034604 — intervention group
Group type: COMPARATOR
Intervention: Intravesical BCG according to International Protocol (control group)
Number of subjects: 47
Study 17034604 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drug regimen
Number of subjects: 47
Study 17034604 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-drug regimen
Number of subjects: 47
Study 17034604 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG with cytotoxic drugs
Number of subjects: 47
Study 17034604 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b combinations
Number of subjects: 47
Study 17034604 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro group
Number of subjects: 47
Study 17034604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 15612142 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 1287
Study 15612142 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated infants)
Number of subjects: 1287
Study 11544459 — intervention group
Group type: EXPERIMENTAL
Intervention: FC1Ps
Number of subjects: 8
Study 9663175 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin once daily
Number of subjects: 60
Study 9663175 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 60
Study 9663175 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SB 216469 twice a day
Number of subjects: 60
Study 9663175 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg SB 216469 twice a day
Number of subjects: 60
Study 9663175 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SB 216469 three times a day
Number of subjects: 60
Study 7816765 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Dose (MD) regimen
Number of subjects: 30
Study 7816765 — intervention group
Group type: COMPARATOR
Intervention: Single Dose (SD) regimen
Number of subjects: 30
Study 7816765 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations of SD and MD
Number of subjects: 30
Study 3076707 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly antimalarial chemoprophylaxis (chloroquine)
Number of subjects: 73
Study 30939923 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives to increase physical activity
Number of subjects: 0
Study 27783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO)
Number of subjects: 13
Study 27783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Epoprostenol Sodium (PGI2)
Number of subjects: 13
Study 26753485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 80
Study 26753485 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 80
Study 23218801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8
Study 23218801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21976055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense albumin-bound paclitaxel (ab-P) 260 mg/m²
Number of subjects: 197
Study 21976055 — intervention group
Group type: COMPARATOR
Intervention: Cremophor-formulated paclitaxel (cf-P) 175 mg/m² plus bevacizumab
Number of subjects: 197
Study 21976055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense doxorubicin (A) 60 mg/m² plus cyclophosphamide (C) 600 mg/m²
Number of subjects: 197
Study 21976055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense albumin-bound paclitaxel (ab-P)
Number of subjects: 197
Study 21976055 — intervention group
Group type: COMPARATOR
Intervention: Cremophor-formulated paclitaxel (cf-P)
Number of subjects: 197
Study 18316163 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia extract (1667.3 mg/day equivalent to 1000 mg HCA/day)
Number of subjects: 44
Study 18316163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16490088 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LMA)
Number of subjects: 30
Study 16490088 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube (LT)
Number of subjects: 30
Study 12592084 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% maize-oil-dissolved oral CsA solution
Number of subjects: 16
Study 12592084 — intervention group
Group type: COMPARATOR
Intervention: Maize oil alone
Number of subjects: 16
Study 10846030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (HCD; approximately 78% carbohydrate)
Number of subjects: 6
Study 10846030 — intervention group
Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (MD; approximately 48% carbohydrate)
Number of subjects: 6
Study 9339943 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative enteral feeding via jejunostomy (fed group)
Number of subjects: 28
Study 8416449 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with IV sedation (lidocaine with adrenaline, bupivacaine, midazolam, alfentanil)
Number of subjects: 125
Study 8416449 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (alfentanil, propofol, atracurium)
Number of subjects: 125
Study 3709032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine HCl 40 mg
Number of subjects: 6
Study 3709032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine HCl 80 mg
Number of subjects: 6
Study 3709032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripelennamine HCl 50 mg
Number of subjects: 6
Study 3709032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripelennamine HCl 100 mg
Number of subjects: 6
Study 3709032 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine with Tripelennamine
Number of subjects: 6
Study 30062941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral stem
Number of subjects: 141
Study 30062941 — intervention group
Group type: COMPARATOR
Intervention: Cementless femoral stem
Number of subjects: 141
Study 26869182 — intervention group
Group type: EXPERIMENTAL
Intervention: Body psychotherapy group (10-week, 90-minute, 20-session manualised group body psychotherapy)
Number of subjects: 275
Study 26869182 — intervention group
Group type: EXPERIMENTAL
Intervention: Body psychotherapy group
Number of subjects: 275
Study 26869182 — intervention group
Group type: COMPARATOR
Intervention: Pilates group (10-week, 90-minute, 20-session group beginners' Pilates class)
Number of subjects: 275
Study 26201718 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sedation supplemented with pain management during mechanical ventilation
Number of subjects: 700
Study 26201718 — intervention group
Group type: COMPARATOR
Intervention: Sedation with a daily wake-up trial
Number of subjects: 700
Study 23054212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day plus Lapatinib 1,500 mg/day
Number of subjects: 75
Study 23054212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg/day plus Lapatinib 1,000 mg/day
Number of subjects: 75
Study 23054212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib and Lapatinib combination therapy
Number of subjects: 75
Study 20875756 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + EDTA with gutta‐percha/AH26
Number of subjects: 0
Study 20875756 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% NaOCl + MTAD with gutta‐percha/AH26
Number of subjects: 0
Study 20875756 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany SE
Number of subjects: 0
Study 20875756 — intervention group
Group type: COMPARATOR
Intervention: Gutta‐percha/AH26
Number of subjects: 0
Study 18433009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (BG)
Number of subjects: 25
Study 18433009 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 25
Study 17170773 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-disc shielding against earth rays
Number of subjects: 80
Study 17170773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TX-disc shielding)
Number of subjects: 80
Study 12438058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.025 mmol/kg
Number of subjects: 94
Study 12438058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.05 mmol/kg
Number of subjects: 94
Study 12438058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.1 mmol/kg
Number of subjects: 94
Study 12438058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine 0.2 mmol/kg
Number of subjects: 94
Study 12438058 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 94
Study 12438058 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of gadobenate dimeglumine
Number of subjects: 94
Study 10326702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based polychemotherapy
Number of subjects: 21
Study 10326702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based polychemotherapy + IL-12 incubation
Number of subjects: 21
Study 10326702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based polychemotherapy + Amifostine pretreatment
Number of subjects: 21
Study 10326702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based polychemotherapy + Amifostine pretreatment + IL-12 incubation
Number of subjects: 21
Study 8606613 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 resection (levels 1 and 2 lymphadenectomy)
Number of subjects: 400
Study 8606613 — intervention group
Group type: COMPARATOR
Intervention: D1 resection (level 1 lymphadenectomy)
Number of subjects: 400
Study 8606613 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 resection with en-bloc pancreatico-splenic resection
Number of subjects: 400
Study 8606613 — intervention group
Group type: EXPERIMENTAL
Intervention: Other patients (not undergoing en-bloc pancreatico-splenic resection)
Number of subjects: 400
Study 2029709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 200 mg
Number of subjects: 16
Study 2029709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 16
Study 2029709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 200 mg plus Aspirin 300 mg
Number of subjects: 16
Study 2029709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7028897 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine syrup (SCMC)
Number of subjects: 58
Study 7028897 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine, phenylephrine with phenylpropanolamine elixir (BPP)
Number of subjects: 58
Study 7028897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 28942681 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Rating Scale (three-factor structure)
Number of subjects: 508
Study 28942681 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Rating Scale (Factor 1: disability items)
Number of subjects: 508
Study 28942681 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Rating Scale (Factor 2: impairment items)
Number of subjects: 508
Study 28942681 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Rating Scale (Factor 3: handicap items)
Number of subjects: 508
Study 28942681 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment factor at admission
Number of subjects: 508
Study 28942681 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability factor at discharge
Number of subjects: 508
Study 27981738 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/d
Number of subjects: 211
Study 27981738 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 1.25 mg/d
Number of subjects: 211
Study 27981738 — intervention group
Group type: COMPARATOR
Intervention: Atrasentan
Number of subjects: 211
Study 25664993 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic shoulder strapping
Number of subjects: 17
Study 25664993 — intervention group
Group type: COMPARATOR
Intervention: Placebo shoulder strapping
Number of subjects: 17
Study 24330220 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced enrollment and engagement outreach (EEE)
Number of subjects: 203
Study 24330220 — intervention group
Group type: COMPARATOR
Intervention: Administrative outreach (AO)
Number of subjects: 203
Study 22850358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 1904
Study 22850358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1904
Study 22850358 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antimalarial drugs
Number of subjects: 1904
Study 19675863 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5mg/day for 4 weeks
Number of subjects: 67
Study 19675863 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 67
Study 19675863 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 67
Study 17276188 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 1230
Study 17276188 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty or vascular brachytherapy
Number of subjects: 1230
Study 11271859 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil
Number of subjects: 0
Study 11271859 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study 11271859 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil (HOSO)
Number of subjects: 0
Study 11271859 — intervention group
Group type: COMPARATOR
Intervention: Palmolein
Number of subjects: 0
Study 9201799 — intervention group
Group type: EXPERIMENTAL
Intervention: abecarnil
Number of subjects: 49
Study 9201799 — intervention group
Group type: COMPARATOR
Intervention: diazepam
Number of subjects: 49
Study 1493085 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 21-132 (20 mg, 40 mg) infused intravenously over 15 min
Number of subjects: 0
Study 1493085 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 21-132 (2 mg to 24 mg) nebulized and inhaled
Number of subjects: 0
Study 1493085 — intervention group
Group type: COMPARATOR
Intervention: Inhaled, nebulized hypertonic sucrose
Number of subjects: 0
Study 1493085 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 21-132 (intravenous and inhaled routes)
Number of subjects: 0
Study 2861620 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 2861620 — intervention group
Group type: COMPARATOR
Intervention: Zimelidine
Number of subjects: 0
Study 31070986 — intervention group
Group type: EXPERIMENTAL
Intervention: IVACFLU-S (15 mcg hemagglutinin per strain)
Number of subjects: 888
Study 31070986 — intervention group
Group type: EXPERIMENTAL
Intervention: IVACFLU-S
Number of subjects: 888
Study 31070986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 888
Study 29797109 — intervention group
Group type: EXPERIMENTAL
Intervention: PG/timolol fixed combination therapy (switched group)
Number of subjects: 51
Study 29797109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding topical ripasudil therapy (added group)
Number of subjects: 51
Study 26688294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral osteotomy performed in a horizontal straight fashion (Group 1, n = 16)
Number of subjects: 30
Study 26688294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral osteotomy performed in parallel to the occlusal plane with a step at the zygomatic buttress (Group 2, n = 14)
Number of subjects: 30
Study 24446825 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about insect type
Number of subjects: 320
Study 24446825 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about contamination processes
Number of subjects: 320
Study 24446825 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the safety of contaminated food
Number of subjects: 320
Study 24446825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of information types (2 of 1, 2, and 3)
Number of subjects: 320
Study 24446825 — intervention group
Group type: EXPERIMENTAL
Intervention: All information
Number of subjects: 320
Study 24446825 — intervention group
Group type: COMPARATOR
Intervention: No information
Number of subjects: 320
Study 22368259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil drops containing Lactobacillus salivarius WB21
Number of subjects: 42
Study 22368259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20237213 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18446440 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face groups
Number of subjects: 0
Study 18446440 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based sessions
Number of subjects: 0
Study 18446440 — intervention group
Group type: COMPARATOR
Intervention: Booklet only
Number of subjects: 0
Study 15733195 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching about stereotype threat in a math test context
Number of subjects: 0
Study 15733195 — intervention group
Group type: COMPARATOR
Intervention: Math test without discussion of stereotype threat
Number of subjects: 0
Study 15733195 — intervention group
Group type: COMPARATOR
Intervention: Problem-solving task
Number of subjects: 0
Study 15733195 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching about stereotype threat
Number of subjects: 0
Study 14632722 — intervention group
Group type: EXPERIMENTAL
Intervention: High mix (HM) [75% lispro (LP) and 25% neutral protamine lispro (NPL)]
Number of subjects: 0
Study 14632722 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 0
Study 14632722 — intervention group
Group type: EXPERIMENTAL
Intervention: High mix (HM)
Number of subjects: 0
Study 14632722 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (HR)
Number of subjects: 0
Study 10570423 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheter
Number of subjects: 144
Study 10570423 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline pleurodesis
Number of subjects: 144
Study 8547676 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg)
Number of subjects: 30
Study 8547676 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and total body irradiation (historical control)
Number of subjects: 30
Study 8547676 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan and cyclophosphamide (combined data)
Number of subjects: 30
Study 8547676 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan and cyclophosphamide (for patients aged 40 to 55 years)
Number of subjects: 30
Study 8547676 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan and cyclophosphamide (for patients receiving unrelated or mismatched related donor marrow)
Number of subjects: 30
Study 1857992 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxon test
Number of subjects: 47
Study 1857992 — intervention group
Group type: COMPARATOR
Intervention: Chewing gum test
Number of subjects: 47
Study 1857992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 47
Study 29978257 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) - hack-squat performed three times a week for 12 weeks at 90% of one repetition maximum (1RM)
Number of subjects: 23
Study 29978257 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - conventional clinical treatment without MST
Number of subjects: 23
Study 27774921 — intervention group
Group type: EXPERIMENTAL
Intervention: Castellani's paint
Number of subjects: 61
Study 27774921 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid ear drops
Number of subjects: 61
Study 27774921 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-impacted cerumen removal
Number of subjects: 61
Study 24335695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-Intensive (DI) chemotherapy (Regimen B, n = 166)
Number of subjects: 328
Study 24335695 — intervention group
Group type: COMPARATOR
Intervention: Standard dose chemotherapy (Regimen A, n = 162)
Number of subjects: 328
Study 23393711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intermittent physical therapy
Number of subjects: 10
Study 23393711 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 10
Study 20862944 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-drug compound anesthesia (Group A)
Number of subjects: 30